STOCK TITAN
  1. Home
  2. Sec-filings
  3. SBEV
  4. [8-K] SPLASH BEVERAGE GROUP, INC. Reports Material Event

Splash Beverage (NYSE: SBEV) pivots to cannabinoid drugs before Endovia rebrand

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Splash Beverage Group, Inc. (SBEV) reported a sharply lower loss from continuing operations as it accelerates a strategic pivot into cannabinoid-based health sciences under the planned Endovia Health Sciences brand. For the six months ended June 30, 2026, loss from continuing operations was approximately $4 million, compared with approximately $11 million for the same period in 2025, an improvement of about $7 million, or 64%, driven primarily by cost-reduction initiatives and exiting alcoholic beverages.

Subsequent to June 30, 2026, the company entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform initially developed for drug-resistant epilepsy, and expanded the license to veterinary applications targeting companion-animal oncology and chronic pain. Splash also signed a development and collaboration agreement with Lupvindol Biosciences Ltd. to lead scientific and FDA regulatory development of a CannEpil-based veterinary product through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug and Conditional Approval pathways. The company is preparing to relaunch CannEpil in the UK, Ireland and select Latin American markets and expects its rebranding to Endovia Health Sciences, including a ticker change, to take effect on the NYSE American beginning August 24, 2026.

Positive

  • Loss from continuing operations improved by ~64% for the first six months of 2026 (approximately $4 million loss versus $11 million a year earlier), reflecting significant cost reductions during the company’s strategic transition.
  • Exclusive global CannEpil® license and veterinary expansion provide a differentiated pharmaceutical-grade cannabinoid platform, with a collaboration to pursue FDA CVM INAD and Conditional Approval pathways that could open regulated human and veterinary therapeutic markets.

Negative

  • The company highlights substantial risks, including its ability to raise capital, meet debt obligations, and comply with NYSE American continued listing standards, explicitly noting the risk that its shares could be delisted.
  • Future success depends heavily on maintaining the CannEpil® license, completing required studies, establishing safety and efficacy, obtaining and maintaining regulatory authorizations, and achieving commercialization, any of which may not occur.

Filing Explained

Alongside its strategic update, the company’s June 30, 2026 cash and equivalents were $242,702, equal to 20 days of historical operating cash use, while the release identifies raising necessary capital as a risk; the transformation therefore remains funding-dependent.

Sources and calculations
  • Cash and equivalents vs quarterly operating cash outflow, in days of cash use $242,702 / ($1,091,680 / 90) = [object Object]
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Loss from continuing operations 1H 2026 $4 million For the six months ended June 30, 2026
Loss from continuing operations 1H 2025 $11 million For the six months ended June 30, 2025
Improvement in loss from continuing operations $7 million Difference between 1H 2026 and 1H 2025 losses from continuing operations
Loss reduction percentage 64% Improvement in loss from continuing operations for the first six months year-over-year
Rebranding effective date August 24, 2026 Expected effective date for name and ticker change to Endovia Health Sciences on NYSE American
Quarter end date June 30, 2026 End date of the second quarter for which results were reported
Investigational New Animal Drug regulatory
"through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug, or INAD,"
A regulatory status that lets a company legally test a new animal drug in clinical trials before it can be approved and sold. Think of it as a temporary, closely supervised permit to study safety and effectiveness in animals; for investors it signals an early but regulated step in a product’s development timeline, with potential value if trials succeed and risks while data and approvals are still pending.
Conditional Approval regulatory
"through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug, or INAD, and Conditional Approval pathways."
Conditional approval is a formal confirmation that a product or plan is permitted to proceed, provided certain specified requirements are met within a designated timeframe. For investors, it signals that approval is nearly complete but depends on the fulfillment of specific conditions, which could influence the final outcome or timeline. This status helps stakeholders assess the likelihood of success while identifying any remaining hurdles.
exclusive global license financial
"Splash entered into an exclusive global license for CannEpil®"
continued listing standards regulatory
"our ability to comply with NYSE American’s continued listing standards and the risk"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
forward-looking statements regulatory
"This press release contains forward-looking statements, including statements regarding the Company’s new strategic focus,"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Loss from continuing operations 1H 2026 $4 million Improved from $11 million in 1H 2025 (64% reduction in loss)

FAQ

How did Splash Beverage Group (SBEV) perform in the first half of 2026?
Splash reported a loss from continuing operations of about $4 million for the six months ended June 30, 2026, versus $11 million a year earlier, an improvement of roughly $7 million or 64%, mainly due to cost-reduction efforts.

What strategic shift is Splash Beverage Group (SBEV) making toward Endovia Health Sciences?
Splash is transitioning from alcoholic beverages to a cannabinoid-based health sciences platform under the planned Endovia Health Sciences brand, focusing on pharmaceutical, veterinary and consumer wellness products based on differentiated cannabinoid technologies such as CannEpil®.

What is the CannEpil® agreement described by Splash Beverage Group (SBEV)?
Splash entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy. The license has been expanded to veterinary applications, initially targeting companion-animal oncology and chronic pain management.

What collaboration did Splash Beverage Group (SBEV) announce with Lupvindol Biosciences?
On July 31, 2026, Splash signed a development and collaboration agreement with Lupvindol Biosciences Ltd., under which Lupvindol will lead scientific and FDA regulatory development of a CannEpil-based veterinary product through INAD and Conditional Approval pathways.

When will Splash Beverage Group (SBEV) rebrand to Endovia Health Sciences on the NYSE American?
Splash stated that its rebranding to Endovia Health Sciences, including a corporate name and ticker symbol change, is expected to take effect on the NYSE American beginning August 24, 2026, reflecting its new cannabinoid health sciences focus.

What key risks did Splash Beverage Group (SBEV) highlight in connection with its new strategy?
Splash cited risks around its ability to raise capital, maintain the CannEpil® license, complete studies, secure and keep regulatory authorizations, meet debt obligations, and comply with NYSE American continued listing standards, noting possible delisting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001553788 0001553788 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 20, 2026

 

SPLASH BEVERAGE GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40471   34-1720075

(State or other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

1112 N. Flagler Drive

Fort Lauderdale, Florida

   33304
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (954) 648-7238

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   SBEV   NYSE American LLC

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 20, 2026, Splash Beverage Group, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit   Description
99.1   Press Release dated August 20, 2026 (furnished herewith)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SPLASH BEVERAGE GROUP, INC.
     
Date: August 20, 2026 By: /s/ Brady Cobb
  Name: Brady Cobb
  Title: Interim Chief Executive Officer

 

 

 

 

 

EXHIBIT 99.1

 

Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences

 

The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold

 

FORT LAUDERDALE, Fla., August 20, 2026 — Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided an update on the Company’s ongoing strategic transformation toward Endovia Health Sciences.

 

For the six months ended June 30, 2026, the Company’s loss from continuing operations was approximately $4 million dollars, compared with approximately $11 million dollars for the six months ended June 30, 2025, representing an improvement of approximately $7 million dollars, or 64%. Management attributes the improvement primarily to significant cost-reduction initiatives that have been implemented over the past six (6) months as the Company has sought to shift its business focus and transition from the sale of alcoholic beverages to the development and commercialization of cannabinoid health and wellness products.

 

Building the Foundation

 

During the second quarter, management remained focused on reducing the Company’s operating cost structure, simplifying the business and strengthening its financial foundation.

 

Key developments included:

 

●Reducing loss from continuing operations by approximately 64% year-over-year for the six-month period;

 

●Continuing to reduce corporate overhead and administrative expenses;

 

●Simplifying the Company’s operating structure and legacy obligations; and

 

●Advancing the strategic repositioning of the business toward pharmaceutical, veterinary and cannabinoid-based health sciences opportunities.

 

“The first half of 2026 was about rebuilding the foundation of our Company,” said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. “Through disciplined execution and significant cost reductions, we expect to reduce our loss from continuing operations by approximately 64% compared with the same period last year. That progress has given us a more efficient operating platform from which to execute the strategic initiatives announced following quarter-end.”

 

 

 

Executing the Transformation

 

Subsequent to June 30, 2026, the Company executed several strategic initiatives that management believes materially reposition the business for its next phase of growth.

 

CannEpil® Licensing

 

In early July 2026 Splash entered into an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy, providing the Company with a differentiated pharmaceutical asset and a foundation for future regulated therapeutic opportunities.

 

Veterinary Expansion

 

The Company subsequently expanded its CannEpil® license to include veterinary applications, initially targeting companion-animal oncology and chronic pain management.

 

Lupvindol Development Collaboration

 

On July 31, 2026, Splash entered into a development and collaboration agreement with Lupvindol Biosciences Ltd. Under the agreement, Lupvindol will lead the scientific and FDA regulatory development of a CannEpil-based veterinary product through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug, or INAD, and Conditional Approval pathways.

 

The collaboration is designed to advance product development, required preclinical and clinical studies, FDA submissions and potential future commercialization and licensing activities.

 

International Commercialization Efforts

 

The Company has also initiated preparations to relaunch CannEpil® through existing commercial and distribution relationships in the United Kingdom, Ireland and select Latin American markets.

 

Endovia Health Sciences

 

Splash has announced its intention to rebrand as Endovia Health Sciences, with a corporate name change and ticker symbol change expected to take effect on the NYSE American beginning on August 24, 2026. The rebranding reflects the Company’s evolution into a diversified cannabinoid-based health sciences platform focused on pharmaceutical commercialization, FDA-regulated human and veterinary therapeutics, and cannabinoid consumer wellness and beverage opportunities.

 

“The actions taken since quarter-end represent the execution phase of the strategy we spent the first half of the year preparing for,” Cobb continued. “We have added a differentiated pharmaceutical platform, expanded into FDA-regulated veterinary therapeutics, engaged an experienced cannabinoid drug-development team, begun rebuilding international commercialization and established a new corporate identity designed to reflect the company we are becoming.”

 

 

 

“Our focus remains straightforward: execute against measurable milestones, allocate capital responsibly and build a diversified cannabinoid-based health sciences platform capable of creating sustainable long-term value for our shareholders.”

 

About Splash Beverage Group, Inc.

 

Splash Beverage Group, Inc. (NYSE American: SBEV) is transitioning toward Endovia Health Sciences, a diversified cannabinoid-based health sciences platform focused on acquiring, developing and commercializing differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets.

 

Where Science Meets Cannabinoid Innovation

 

More Information

 

Splash Beverage Group

 

Contact Information

 

Splash Beverage Group
Info@SplashBeverageGroup.com

 

Media Contact

 

Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements, including statements regarding the Company’s new strategic focus, efforts towards the development and commercialization of pharmaceutical products for humans and animals, anticipated trends and expectations for the Company’s business and industry and goals and expectations with respect to the Company’s new business strategy.

 

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially, including the Company’s ability to raise the necessary capital to finance the its operations and business plan, satisfy its contractual obligations including our ability to maintain the license under the license agreement for the CannEpil® product on which the Company’s initial focus depends and related agreements in connection therewith, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, protect intellectual property and the risk that competitors market the same or similar products, our commercialization or strategic-partnering arrangements, the risk that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, our ability to comply with NYSE American’s continued listing standards and the risk that we may be delisted, the possibility that our expectations and perceived benefits with respect to our business plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, or obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

 

Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Form S-1 filed on August 7, 2026, as amended. The Company undertakes no obligation to update forward-looking statements except as required by law.

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents